Lexaria Bioscience Corp. (LEXX)
- Previous Close
2.2400 - Open
2.2000 - Bid 2.1700 x 100
- Ask 2.2700 x 100
- Day's Range
2.1800 - 2.2800 - 52 Week Range
0.6490 - 6.8500 - Volume
97,836 - Avg. Volume
493,850 - Market Cap (intraday)
28.864M - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6600 - Earnings Date Jul 12, 2024 - Jul 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
lexariabioscience.comRecent News: LEXX
Performance Overview: LEXX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LEXX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LEXX
Valuation Measures
Market Cap
28.86M
Enterprise Value
24.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
47.73
Price/Book (mrq)
4.43
Enterprise Value/Revenue
59.84
Enterprise Value/EBITDA
-4.67
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.36%
Return on Equity (ttm)
-101.49%
Revenue (ttm)
404.73k
Net Income Avi to Common (ttm)
-5.44M
Diluted EPS (ttm)
-0.6600
Balance Sheet and Cash Flow
Total Cash (mrq)
4.79M
Total Debt/Equity (mrq)
2.42%
Levered Free Cash Flow (ttm)
-3.45M